瑞博生物登陆港交所：高瓴创投六年耐心陪伴，再获一个百亿IPO

Core Viewpoint - Suzhou Rebio Technology Co., Ltd. (Rebio) officially listed on the Hong Kong Stock Exchange on January 9, 2026, with a market capitalization exceeding HKD 14 billion, marking it as the first Chinese small nucleic acid drug company [3] Group 1: Company Overview - Rebio was founded in 2007 by Liang Zicai and Zhang Hongyan, who aimed to promote original research and innovation in China [5] - The company established China's first small nucleic acid base and has developed a comprehensive technology system covering target discovery to clinical development [5] - Rebio has created one of the largest siRNA drug pipelines globally, with seven self-developed drug assets currently in clinical trials [5] Group 2: Investment and Support - Hillhouse Capital has been a significant investor in Rebio since leading its Series C financing in March 2020 and further participating in the Series C+ round [3][6] - Hillhouse's long-term support has been crucial in clinical development discussions and strategic partnerships, including collaborations with Boehringer Ingelheim and Qilu Pharmaceutical, valued at over USD 2 billion [7] - The investment strategy emphasizes the importance of "patient capital" in the long and uncertain journey of innovative drug development [7] Group 3: Industry Context - The development of innovative drugs in China has become clearer, with patient capital playing an irreplaceable role in this process [8] - The industry faces challenges such as long research cycles, high costs, and low overall success rates, which test the research and post-investment capabilities of investment institutions [7]